P100 SPRC-leonurine Conjugate Alleviates Ischemia Induced Cardiac Fibrosis Through ROS-Stat3 Pathway

Shanshan Luo,Xianfeng Gu,Yi-Zhun Zhu

DOI: https://doi.org/10.1016/j.niox.2014.03.150

2014-01-01

Nitric Oxide - Biology and Chemistry

Abstract:Hydrogen sulfide plays various roles in cardiovascular system. SPRC is a kind of H2S donor in our lab whose cardio-protective effects have been verified. To improve its efficiency and pharmacokinetics properties, we have designed, synthesized SPRC-Leonurine conjugates and evaluated its effects on H2S release and CSE expression in vitro, while the in vivo data remains unrevealed. Using rat cardiac infarction model induced by LAD, We demonstrated that administration of Conjugates for 3 days could notably decrease the expression of inflammatory factor IL-6 and TNF-alpha as well as ROS production. After 2 weeks and 6 weeks treatment, the infarction area was significantly reduced by 25% and 30%, respectively; echocardiography showed improved cardiac function, furthermore, cardiac fibrosis was alleviated and Collagen one, Collagen three, alpha-SMA, MMP-2, MMP-9 were reduced. Interestingly, the Conjugates could effectively improve phosphor-Stat3 expression in both remote and border zones, to investigate whether Stat-3 was essential in the Conjugates' anti-fibrosis effect, Stat3 inhibitor and siRNA were used. Ang2 was used to induce fibrosis model on primary adult rat cardiac fibroblasts. The results showed that Ang2 could induce burst of ROS followed by fibroblasts transition which was failed to be quenched by Conjugates with absence of phosphor-Stat3. All together, our results showed that the Conjugate could effectively reduce production of ROS, thus decreasing inflammatory response at earlier stage of myocardial infarction (3 days) and inhibiting cardiac remodeling by reducing cardiac fibrosis at the later stage (2 weeks and 6 weeks).